By proceeding, you agree to our Terms of Use and Privacy Policy.
Tarus Therapeutics is a biotechnology company focused on nucleotide metabolism in cancer. The company’s lead programs target the immunosuppressive adenosine pathway in the tumor microenvironment (TME) for the treatment of resistant cancers.
10-12 May 2022
Maximize the Clinical & Commercial Opportunity of the Adenosine-Pathway as a Second-Generation Immuno-Oncology Target A plethora of showstopping clinical trial data readouts are being met with refreshed excitement, enthusiasm and R&D investment for a
Event Ended
USA
Paid
Boston